An oral GLP-1 receptor agonist, orfoglipron, has demonstrated promising results in phase II trials for obesity, with weight loss ranging from 9.4% to 14.7% over 36 weeks, comparable to other injectable GLP-1 analogues (142)
Lillys new self-pay pharmacy, LillyDirect, allows patients with a valid, on-label prescription to purchase the vials, effectively competing with potentially unsafe but more affordable counterfeit, fake, unsafe or untested knockoffs of Lilly's medications, according to the release
they do not establish any therapeutic benefit for any condition, and critically they are not studies of the no-DAC form used in blends
A positive or negative result should not be interpreted as proof that a substance is safe
Research Citations National Library of Medicine